Roche Holding AGRHHBY announced that the phase III study, HAVEN 1, met its primary endpoint.
We note that Roche has underperformed the Zacks classified Large Cap Pharmaceuticals industry in the year-to-date period. In fact, the stock has lost 18.2% during this period, compared with a drop of 6.1% for the industry.
Coming back to the latest news, the randomized, multicenter, open-label, phase III study evaluating the efficacy, safety and pharmacokinetics of emicizumab prophylaxis versus no prophylaxis in patients with hemophilia (12 years of age or older) and inhibitors to factor VIII.
The study evaluated emicizumab prophylaxis in patients of 12 years of age or older with hemophilia A and inhibitors to factor VIII.
The data from the study showed a statistically significant reduction in the number of bleeds over time in patients treated with emicizumab prophylaxis as compared to those patients who do not receive prophylactic treatment.
Additionally, the study also met all secondary endpoints- a statistically significant reduction in the number of bleeds over time with emicizumab prophylaxis treatment in an intra-patient comparison in patients who had received prior bypassing agent prophylaxis treatment.
We note that HAVEN 1 is the first Phase III study in the emicizumab clinical development program to report results.
As per Roche, Hemophilia A affects around 320,000 people globally while approximately 50-60% of whom have a severe form of the disorder.
Roche has a strong presence in the oncology market. In particular, the company dominates the breast cancer space on robust demand for its HER2 franchise drugs. The company is also making efforts to develop its portfolio beyond oncology into immunology. We remind investors that hematology is a major area of focus of research and development at Roche.?? Roche???s hematology portfolio boasts approved drugs including MabThera/Rituxan, Gazyva/Gazyvaro, and Venclexta in collaboration with AbbVie ABBV , as well as an encouraging pipeline comprising candidates like polatuzumab vedotin/RG7596 and and a small molecule antagonist of MDM2 (idasanutlin/RG7388). Beyond malignancy, the haematology pipeline also consists emicizumab.
ROCHE HLDG LTD Price and Consensus
Roche currently carries a Zacks Rank #4 (Sell).
Key Picks in the Sector
A couple of better-ranked stocks in the health care sector include Heska Corp. HSKA , and Vanda Pharmaceuticals VNDA . Each of these stocks sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today???s Zacks #1 Rank stocks here .
Heska???s earnings estimates increased from $1.13 to $1.35 for 2016 and from $1.38 to $1.53 for 2017 over the last 60 days. The company posted a positive earnings surprise in all of the four trailing quarters with an average beat of 301.64%. Its share price has increased 92.1% year to date.
Vanda???s loss estimates for 2016 narrowed from 62 cents to 52 cents, while its earnings estimates for 2017 increased from 13 cents to 22 cents over the last 60 days. The company posted a positive earnings surprise in three of the four trailing quarters with an average beat of 56.65%. Its share price has surged almost 70.7% year to date.
Zacks' Top Investment Ideas for Long-Term Profit
How would you like to see our best recommendations to help you find today???s most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report